使用或不使用超活性促性腺激素释放激素激动剂的人供精人工授精中 HMG/HCG 超排卵的比较。

Comparison of HMG/HCG superovulation for AID with or without superactive GnRH agonist.

作者信息

Gerris J, Jacquemyn Y, Desmedt E, Delbeke L, Buytaert P

机构信息

Department of Obstetrics and Gynaecology, University Hospital, Antwerp, Belgium.

出版信息

Hum Reprod. 1989 Nov;4(8):937-40. doi: 10.1093/oxfordjournals.humrep.a137016.

DOI:10.1093/oxfordjournals.humrep.a137016

PMID:2515211

Abstract

New methods of ovulation induction have been discovered and perfected in recent years. Among others, gonadotrophin-releasing hormone (GnRH) agonists are being used increasingly in the treatment of ovulatory infertility. In a prospective study, 24 women undergoing artificial insemination with donor sperm (AID) and facing failure of treatment because of ovulation disorders, were treated with human menopausal gonadotrophin/human chorionic gonadotrophin (HMG/HCG) superovulation with or without pituitary densensitization using a superactive luteinizing hormone-releasing hormone (LHRH) agonist, buserelin (BUS), Suprefact (Hoechst, Frankfurt a/Main, FRG). In 86 cycles stimulated with HMG/HCG no pregnancy occurred, whereas 12 pregnancies occurred in the same group of patients after a total of 43 BUS/HMG/HCG stimulation cycles. Superactive LHRH agonists have a definite place in the treatment of AID patients presenting with refractory ovulation disorders and/or luteal insufficiency.

摘要

近年来，已发现并完善了新的促排卵方法。其中，促性腺激素释放激素（GnRH）激动剂在排卵障碍性不孕症的治疗中应用越来越广泛。在一项前瞻性研究中，24名因排卵障碍而接受供精人工授精（AID）且治疗失败的女性，接受了人绝经期促性腺激素/人绒毛膜促性腺激素（HMG/HCG）超促排卵治疗，使用超活性促黄体生成素释放激素（LHRH）激动剂布舍瑞林（BUS）、Suprefact（德国赫斯特公司，美因河畔法兰克福）进行垂体脱敏或不进行垂体脱敏。在86个接受HMG/HCG刺激的周期中未发生妊娠，而在同一组患者中，经过总共43个BUS/HMG/HCG刺激周期后有12例妊娠。超活性LHRH激动剂在治疗难治性排卵障碍和/或黄体功能不全的AID患者中具有明确的地位。